LOLauren Oakden-Rayner

Lauren Oakden-Rayner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Recognitions

Top Cited Young Scholar (2026)
Top Cited Scholar (2026)

Lauren Oakden-Rayner has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods: a Korean translation

    by Gary S Collins, Karel G M Moons, Paula Dhiman, Richard D Riley, Andrew L Beam, Ben Van Calster, Marzyeh Ghassemi, Xiaoxuan Liu, Johannes B Reitsma, Maarten van Smeden, et al.

    TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods: a Korean translation


  • Top Cited Papers
    Open Access

    PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods

    by Karel G M Moons, Johanna A A Damen, Tabea Kaul, Lotty Hooft, Constanza Andaur Navarro, Paula Dhiman, Andrew L Beam, Ben Van Calster, Leo Anthony Celi, Spiros Denaxas, et al.

    The Prediction model Risk Of Bias ASsessment Tool (PROBAST) is used to assess the quality, risk of bias, and applicability of prediction models or algorithms and of prediction model/algorithm studies. Since PROBAST’s introduction in 2019, much progress has been made in the methodology for prediction modelling and in the use of artificial intelligence, including machine learning, techniques. An update to PROBAST-2019 is thus needed. This article describes the development of PROBAST+AI. PROBAST+AI consists of two distinctive parts: model development and model evaluation. For model development, PROBAST+AI users assess quality and applicability using 16 targeted signalling questions. For model evaluation, PROBAST+AI users assess the risk of bias and applicability using 18 targeted signalling questions. Both parts contain four domains: participants and data sources, predictors, outcome, and analysis. Applicability of the prediction model is rated for the participants and data sources, predictors, and outcome domains. PROBAST+AI may replace the original PROBAST tool and allows all key stakeholders (eg, model developers, AI companies, researchers, editors, reviewers, healthcare professionals, guideline developers, and policy organisations) to examine the quality, risk of bias, and applicability of any type of prediction model in the healthcare sector, irrespective of whether regression modelling or AI techniques are used.


  • Top Cited Papers

    CANAIRI: the Collaboration for Translational Artificial Intelligence Trials in healthcare

    by Melissa D. McCradden, Alex John London, Judy Wawira Gichoya, Mark Sendak, Lauren Erdman, Ian Stedman, Lauren Oakden-Rayner, Ismail Akrout, James A. Anderson, Lesley-Anne Farmer, et al.


  • Tackling Algorithmic Bias and Promoting Transparency in Health Datasets: The STANDING Together Consensus Recommendations

    by Joseph E. Alderman, Joanne Palmer, Elinor Laws, Melissa D. McCradden, Johan Ordish, Marzyeh Ghassemi, Stephen R. Pfohl, Negar Rostamzadeh, Heather Cole-Lewis, Ben Glocker, et al.


  • Top Cited Papers
    Open Access

    TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods

    by Gary S Collins, Karel G M Moons, Paula Dhiman, Richard D Riley, Andrew L Beam, Ben Van Calster, Marzyeh Ghassemi, Xiaoxuan Liu, Johannes B Reitsma, Maarten van Smeden, et al.

    The TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) statement was published in 2015 to provide the minimum reporting recommendations for studies developing or evaluating the performance of a prediction model. Methodological advances in the field of prediction have since included the widespread use of artificial intelligence (AI) powered by machine learning methods to develop prediction models. An update to the TRIPOD statement is thus needed. TRIPOD+AI provides harmonised guidance for reporting prediction model studies, irrespective of whether regression modelling or machine learning methods have been used. The new checklist supersedes the TRIPOD 2015 checklist, which should no longer be used. This article describes the development of TRIPOD+AI and presents the expanded 27 item checklist with more detailed explanation of each reporting recommendation, and the TRIPOD+AI for Abstracts checklist. TRIPOD+AI aims to promote the complete, accurate, and transparent reporting of studies that develop a prediction model or evaluate its performance. Complete reporting will facilitate study appraisal, model evaluation, and model implementation.


  • Open Access

    Developing, purchasing, implementing and monitoring AI tools in radiology: Practical considerations. A multi‐society statement from the ACR, CAR, ESR, RANZCR & RSNA

    by Adrian P Brady, Bibb Allen, Jaron Chong, Elmar Kotter, Nina Kottler, John Mongan, Lauren Oakden‐Rayner, Daniel Pinto dos Santos, An Tang, Christoph Wald, et al.

    Summary: Artificial Intelligence (AI) carries the potential for unprecedented disruption in radiology, with possible positive and negative consequences. The integration of AI in radiology holds the potential to revolutionize healthcare practices by advancing diagnosis, quantification, and management of multiple medical conditions. Nevertheless, the ever‐growing availability of AI tools in radiology highlights an increasing need to critically evaluate claims for its utility and to differentiate safe product offerings from potentially harmful, or fundamentally unhelpful ones. This multi‐society paper, presenting the views of Radiology Societies in the USA, Canada, Europe, Australia, and New Zealand, defines the potential practical problems and ethical issues surrounding the incorporation of AI into radiological practice. In addition to delineating the main points of concern that developers, regulators, and purchasers of AI tools should consider prior to their introduction into clinical practice, this statement also suggests methods to monitor their stability and safety in clinical use, and their suitability for possible autonomous function. This statement is intended to serve as a useful summary of the practical issues which should be considered by all parties involved in the development of radiology AI resources, and their implementation as clinical tools.


  • Top Cited Papers
    Open Access

    Developing, Purchasing, Implementing and Monitoring AI Tools in Radiology: Practical Considerations. A Multi-Society Statement from the ACR, CAR, ESR, RANZCR and RSNA

    by Adrian P. Brady, Bibb Allen, Jaron Chong, Elmar Kotter, Nina Kottler, John Mongan, Lauren Oakden-Rayner, Daniel Pinto dos Santos, An Tang, Christoph Wald, et al.

    Artificial Intelligence (AI) carries the potential for unprecedented disruption in radiology, with possible positive and negative consequences. The integration of AI in radiology holds the potential to revolutionize healthcare practices by advancing diagnosis, quantification, and management of multiple medical conditions. Nevertheless, the ever-growing availability of AI tools in radiology highlights an increasing need to critically evaluate claims for its utility and to differentiate safe product offerings from potentially harmful, or fundamentally unhelpful ones. This multi-society paper, presenting the views of Radiology Societies in the USA, Canada, Europe, Australia, and New Zealand, defines the potential practical problems and ethical issues surrounding the incorporation of AI into radiological practice. In addition to delineating the main points of concern that developers, regulators, and purchasers of AI tools should consider prior to their introduction into clinical practice, this statement also suggests methods to monitor their stability and safety in clinical use, and their suitability for possible autonomous function. This statement is intended to serve as a useful summary of the practical issues which should be considered by all parties involved in the development of radiology AI resources, and their implementation as clinical tools. This article is simultaneously published in Insights into Imaging (DOI 10.1186/s13244-023-01541-3), Journal of Medical Imaging and Radiation Oncology (DOI 10.1111/1754-9485.13612), Canadian Association of Radiologists Journal (DOI 10.1177/08465371231222229), Journal of the American College of Radiology (DOI 10.1016/j.jacr.2023.12.005), and Radiology: Artificial Intelligence (DOI 10.1148/ryai.230513). Keywords: Artificial Intelligence, Radiology, Automation, Machine Learning Published under a CC BY 4.0 license. ©The Author(s) 2024. Editor's Note: The RSNA Board of Directors has endorsed this article. It has not undergone review or editing by this journal.


  • Open Access

    Taking Off with AI: Lessons from Aviation for Healthcare

    by Elizabeth Bondi-Kelly, Tom Hartvigsen, Lindsay M Sanneman, Swami Sankaranarayanan, Zach Harned, Grace Wickerson, Judy Wawira Gichoya, Lauren Oakden-Rayner, Leo Anthony Celi, Matthew P Lungren, et al.


  • Open Access

    What's fair is… fair? Presenting JustEFAB, an ethical framework for operationalizing medical ethics and social justice in the integration of clinical machine learning

    by Melissa Mccradden, Oluwadara Odusi, Shalmali Joshi, Ismail Akrout, Kagiso Ndlovu, Ben Glocker, Gabriel Maicas, Xiaoxuan Liu, Mjaye Mazwi, Tee Garnett, et al.

    The problem of algorithmic bias represents an ethical threat to the fair treatment of patients when their care involves machine learning (ML) models informing clinical decision-making. The design, development, testing, and integration of ML models therefore require a lifecycle approach to bias identification and mitigation efforts. Presently, most work focuses on the ML tool alone, neglecting the larger sociotechnical context in which these models operate. Moreover, the narrow focus on technical definitions of fairness must be integrated within the larger context of medical ethics in order to facilitate equitable care with ML. Drawing from principles of medical ethics, research ethics, feminist philosophy of science, and justice-based theories, we describe the Justice, Equity, Fairness, and Anti-Bias (JustEFAB) guideline intended to support the design, testing, validation, and clinical evaluation of ML models with respect to algorithmic fairness. This paper describes JustEFAB's development and vetting through multiple advisory groups and the lifecycle approach to addressing fairness in clinical ML tools. We present an ethical decision-making framework to support design and development, adjudication between ethical values as design choices, silent trial evaluation, and prospective clinical evaluation guided by medical ethics and social justice principles. We provide some preliminary considerations for oversight and safety to support ongoing attention to fairness issues. We envision this guideline as useful to many stakeholders, including ML developers, healthcare decision-makers, research ethics committees, regulators, and other parties who have interest in the fair and judicious use of clinical ML tools.


  • Tackling bias in AI health datasets through the STANDING Together initiative

    by Shaswath Ganapathi, Jo Palmer, Joseph E. Alderman, Melanie Calvert, Cyrus Espinoza, Jacqui Gath, Marzyeh Ghassemi, Katherine Heller, Francis Mckay, Alan Karthikesalingam, et al.